The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals

Ethics and the Pharmaceutical Industry

Volumn , Issue , 2005, Pages 225-248

  Hay, Joel W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927082921     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511610769.020     Document Type: Chapter

References (85)

1. Levit K, Smith C, Cowan C, Sensenig A, Catlin A, and the Health Accounts Team, “Health Spending Rebound Continues in 2002,” Health Affairs, 2004, 23(1): 147-59.
2. Levit K, Smith C, Cowan C, Sensenig A, Catlin A, and the Health Accounts Team, “Health Spending Rebound Continues in 2002,” Health Affairs, 2004, 23(1): 147-59.
3. Kaiser Family Foundation, “Prescription Drug Trends: A Chartbook Update, June 2001.” Available at www.kff.org/rxdrugs Accessed July 2004.
4. Reinhardt U, Hussey P, and Anderson G, “Cross-National Comparisons of Health Systems Using OECD Data, 1999,” Health Affairs, 2002, 21(3): 169-81.
5. A superior good as defined by economists is a good for which an increase in income causes an increase in demand, and the income elasticity of demand is positive and greater than one. A superior good is also termed a luxury good.
6. Murphy KM, and Topel RH, Eds. Measuring the Gains from Medical Research: An Economic Approach (Chicago: University of Chicago Press, 2003).
7. Reinhardt U, Hussey P, and Anderson G, “U.S. Health Care Spending in an International Context: Why Is U.S. Spending So High, and Can We Afford It?” Health Affairs, 2004, 23(3): 10-25.
8. Chernew ME, Hirth RA, and Cutler DM, “Increased Spending on Health Care: How Much Can the United States Afford?” Health Affairs, 2003, 22(4): 15-25.
9. Available at www.schoolscience.co.uk/content/4/biology/glaxo/pmb1 trade1.html Accessed July 2004.
10. “TheTrouble with Cheap Drugs,” The Economist, January 29, 2004.Available at www.economist.com/displayStory.cfm?Story ID=2388708 Accessed July 2004.
11. Krupnick AJ, “Valuing Health Outcomes: Policy Choices and Technical Issues,” Resources for the Future Report.Washington, D.C., 2004.
12. Hay J, “Evaluation and Review of Pharmacoeconomic Models,” Expert Opinion on Pharmacotherapy, 2004, 5(9): 1867-80.
13. Gold M, Siegel J, Russell L, and Weinstein M, Cost-Effectiveness in Health and Medicine (New York: Oxford University Press, 1996).
14. Weinstein M, “From Cost-Effectiveness Ratios to Resource Allocation,” in Sloan F, Ed., Valuing Health Care (New York: Cambridge University Press, 1995).
15. Bureau of Labor Statistics, “Employer Costs for Employee Compensation-March 2004.” Available at www.bls.gov/ncs/ect/home.htm Accessed July 2004.
16. Viscusi WK, and Aldy JE, “The Value of a Statistical Life: A Critical Review of Market Estimates Around the World,” Journal of Risk and Uncertainty, 2003, 28(1): 5-76.
17. Wagstaff A, “QALYs and the Equity-Efficiency Trade-Off,” Journal of Health Economics, 1991, 10: 21-41.
18. Gold M, Siegel J, Russell L, and Weinstein M, Cost-Effectiveness in Health and Medicine.
19. Drummond M, Torrance G, and Mason J, “Cost-Effectiveness League Tables: More Harm Than Good,” Social Science and Medicine, 1993, 37: 33-40.
20. The Harvard Center for Risk Analysis maintains an updated list of cost-effectiveness results for many pharmaceuticals and other healthcare interventions.Available atwww.hsph.harvard.edu/cearegistry?Accessed July 2004.
21. Bingham M, Johnson FR, and Miller D, “Modeling Choice Behavior for New Pharmaceutical Products,” Value in Health, 2001, 4(1): 1-13.
22. Hay J, “Conjoint Analysis in Pharmaceutical Research,” Journal of Managed Care Pharmacy, 2002, 8(3): 206-9.
23. Johannesson M, “The Relationship between Cost-Effectiveness Analysis and Cost-Benefit Analysis,” Social Science and Medicine, 1995, 41: 483-9.
24. Bleichrodt H, and Quiggin J, “Life Cycle Preferences over Consumption and Health: When Is Cost-Effectiveness Analysis Equivalent to Cost-Benefit Analysis?” Journal of Health Economics, 1999, 18: 681-708.
25. Garber AM, and Phelps CE, “Economic Foundations of Cost Effectiveness Analysis,” Journal of Health Economics, 1997, 16: 1-31.
26. Klose T, “A Utility-Theoretic Model for QALYs andWillingness to Pay,” Health Economics, 2003, 12: 17-31.
27. Letourneau-Wagner J, Hay J, “The Cost Impacts of Vaccination in the United States: An Overview,” Managed Care Consultant 2005, 4[2]: 11-25.
28. Topol E, “Good Riddance to a Bad Drug,” Editorial Opinion, New York Times, October 2, 2004.
29. Spiegel BMR, Targownik L, Dulai GS, and Gralnek IM, “The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis,” Annals of Internal Medicine, 2003; 138: 795-806.
30. www.hsph.harvard.edu/ceareregistry Accessed July 2004.
31. Wennberg JE, “Dealing with Medical Practice Variations: A Proposal for Action,” Health Affairs, 1984, Summer: 6-32.
32. Wennberg JE and Gittelsohn A, “Small Area Variations in Health Care Delivery,” Science, 1973, 182: 1102-8.
33. Available at www.rand.org Accessed July 2004.
34. Schuster MA, McGlynn EA, and Brook RH, “How Good Is the Quality of Health Care in the United States?” Milbank Quarterly, 1998, 76(4): 517-63, 509.
35. Leape LL, Park RE, Bashore TM, Harrison JK, Davidson CJ, and Brook RH, “Effect of Variability in the Interpretation of Coronary Angiograms on the Appropriateness of Use of Coronary Revascularization Procedures,” American Heart Journal, January 2000, 139(1, Part 1): 106-13.
36. Schuster MA, McGlynn EA, and Brook RH, “How Good Is the Quality of Health Care in the United States?”
37. Reinhardt U, Hussey P, and Anderson G, “Cross-National Comparisons of Health Systems Using OECD Data.”
38. Murphy KM, and Topel RH, Eds., Measuring the Gains from Medical Research.
39. Mushkin S, Biomedical Research: Costs and Benefits (Cambridge, MA: Ballinger Publishing Co., 1979).
40. Cutler DM, and McClellan M, “Is Technological Change in Medicine Worth It?” Health Affairs, 2001, 20(5): 11-29.
41. Murphy KM, and Topel RH, Eds., Measuring the Gains from Medical Research.
42. Available atwww.washingtonpost.com/wp-dyn/articles/A27932-2004Jul4.html Accessed July 2004.
43. Available at www.phrma.org/issues/researchdev?Accessed July 2004.
44. Cutler DM, and McClellan M, “Is Technological Change in Medicine Worth It?” Health Affairs, 2001, 20(5): 11-29.
45. Cutler DM, and McClellan M, “The Trouble with Cheap Drugs,” The Economist, January 29, 2004.
46. Similar concerns can be seen within the United States looking at the market for childhood vaccines. Unlike other pharmaceutical products, the federal Centers for Disease Control have purchased nearly half of all childhood vaccines used in the United States at heavily discounted prices for over a decade. As a result, vaccine R&D has grown more slowly than other pharmaceutical R&D, the number ofU.S. vaccine manufacturers has dropped from dozens to five, severe vaccine shortages occur regularly, and many childhood vaccines have only a single supplier.
47. Lichtenberg FR, “Are the Benefits of Newer Drugs Worth Their Cost? Evidence from the MEPS,” Health Affairs, 2001, 20(5): 241-51.
48. Lichtenberg FR, “The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001,” NBER Working Paper No. 9754, June 2003.
49. Garrison L, and Towse A, “The Drug Budget Silo Mentality in Europe: An Overview,” Value in Health, 2003, 6(Supplement 1): S1-S6.
50. Horn SD, Sharkey PD, and Phillips-Harris C, “Formulary Limitations and the Elderly: Results from the Managed Care Outcomes Project,” American Journal of Managed Care, 1998, 4(8): 1105-13.
51. Soumerai SB, Avom J, Ross-Degnan D, et al., “Payment Restrictions for Prescription Drugs under Medicaid: Effects on Therapy, Cost, and Equity,” New England Journal of Medicine, 1987, 317(9): 550-56.
52. Soumerai SB, Ross-Degnan D, Avom J, et al., “Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes,” New England Journal of Medicine, 1991, 325(15): 1072-7.
53. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al., “Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia,” New England Journal of Medicine, 1994, 331(10): 650-55.
54. Tamblyn R, Laprise R, Hanley J, et al., “Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons,” Journal of the American Medical Association, 2001, 285(4): 421-9.
55. The input-focused paradigm is exemplified by the old saw, “the operation was successful, although the patient died.”
56. Department of Health Housing and Community Services, Australia, Guidelines for the Pharmaceutical Industry on the Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee (Canberra: AGPS, 1992).
57. Hill SR, Mitchell AS, and Henry DA, “Problems with the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme,” JAMA, 2000, 283(16): 2116-21.
58. Langley PC, “Focusing Pharmacoeconomic Activities: Reimbursement or the Drug Life Cycle?” Current Medical Research Opinion, 2004, 20(2): 181-8.
59. Hay J, “Pharmacoeconomic Guidelines: Where Do We Go from Here?” Value in Health, 2001, 4(3): 211.
60. Hjelmgren J, Berggren F, and Andersson F, “Health Economic Guidelines: Similarities, Differences and Some Implications,” Value in Health, 2001, 4: 225-50.
61. Siegel JE, Torrance GW, Russell LB, et al., “Guidelines for Pharmacoeconomic Studies. Recommendations for the Panel on Cost-Effectiveness in Health and Medicine,” PharmacoEconomics, 1997, 11: 159-68.
62. Drummond MF, and Jefferson TO, “Guidelines for Authors and Peer Reviewers of Economic Submissions to the BMJ,” BMJ, 1996, 313: 275-83.
63. Available at www.ispor.org/PEguidelines/COMP1.asp Accessed July 2004.
64. Fry RN, Avey SG, and Sullivan SD, “The Academy of Managed Care Pharmacy Format for Formulary Submissions: An Evolving Standard,” Value in Health, 2003, 6(5): 505-21.
65. Dr. Mark McClellan, the CMS Administrator, has recently announced that Medicare will be demanding more rigorous outcomes evidence before approving new therapies for payment. See Kolata G, “Medicare Covers New Treatments with a Catch,” New York Times, November 5, 2004.
66. Havighurst C, Public Law Research Paper No. 20, Duke Law School, Indiana Law Review, 2001, 34: 395.
67. Available at www.nice.uk.org Accessed July 2004;
68. Garrison L and Towse A, “The Drug Budget Silo Mentality in Europe.”
69. This pre-NICE period is now referred to as the No Assessment or Utilization of Good Health Technology Years (NAUGHTY) era.
70. Available atwww.ispor.org/peguidelines/COMP1.asp Accessed July 2004.
71. Chiou C-F, Hay J, Wallace J, Bloom B, Neumann P, Sullivan S, Yu H-T, Keeler E, Henning J, and Ofman J, “Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies,” Medical Care, 2003, 41: 32-44.
72. Ofman J, Sullivan S, Neumann P, Chiou C-F, Henning J, and Hay J, “Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES,” Journal of Managed Care Pharmacy, 2003, 9(1): 53-62.
73. Mather D, “Do Decision Makers Really Need Health Economic Data?” Value in Health, 2003, 6(4): 404-6.
74. Campen D, “The Bleeding Edge of Decision Making in Managed Health Care-Kaiser-Permanente’s Model for Formulary Development,” Value in Health, 2002, 5(5): 383-9.
75. Connolly C, “Drugmakers Protect Their Turf,” The Washington Post, November 21, 2003.
76. Calfee J, “The Grim Economics of Pharmaceutical Importation,” American Enterprise Institute, November 2003. Available at www. aei.org Accessed February 2004.
77. Calfee J, “2004 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds,” March 23, 2004. Available at www.cms.hhs.gov/publications?trusteesreport/2004/tr.pdf Accessed July 2004.
78. Fumento M, Bioevolution: How Biotechnology Is Changing Our World (San Francisco: Encounter Books, 2003).
79. Liu L, Rettenmaier AJ, Saving TR, “How Large Is the Federal Government’s Debt?” National Center for Policy Analysis, Policy Report No. 263, October 30, 2003. Available at www.ncpa.org/pub/st?st263?Accessed July 2004.
80. Hay J, and Yu W, “Drug Patents and Prices, Can We Achieve Better Outcomes?” in Triplett J, Ed., Measuring the Prices of Medical Treatments (Washington, D.C.: Brookings Press, 1999), pp. 152-95.
81. Hay J, and Yu W, “Pharmacoeconomics and Outcomes Research: Expanding the Health Care “Outcomes” Market,” Value in Health, 2000, 3(3): 181-5.
82. Kremer M, “Patent Buyouts:AMechanism for Encouraging Innovation.” Quarterly Journal of Economics, 1998, November: 1137-7.
83. Kremer M, 2000, “Creating Markets for New Vaccines. Part I: Rationale,” NBER Working Paper, May 12, 2000. Available at www.nber.org Accessed May 26, 2005
84. Kremer M, 2000, “Creating Markets for New Vaccines. Part II: Design Issues,” NBER Working Paper, May 12, 2000. Available at www.nber.org Accessed May 26, 2005.
85. Garber AM, “Cost-Effectiveness and Evidence Evaluation As Criteria for Coverage Policy,” Health Affairs Web Exclusive, 2004, W4: 284-96. Available at www.healthaffairs.org/WebExclusives.php Accessed May 25, 2005.